|College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer|
AC Wolff, ME Hammond, JN Schwartz, KL Hagerty, DC Allred, RJ Cote, ...
J clin oncol 25 (1), 118-145, 2007
|Circulating tumor cells, disease progression, and survival in metastatic breast cancer|
M Cristofanilli, GT Budd, MJ Ellis, A Stopeck, J Matera, MC Miller, ...
New England Journal of Medicine 351 (8), 781-791, 2004
|ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome|
C Ginestier, MH Hur, E Charafe-Jauffret, F Monville, J Dutcher, M Brown, ...
Cell stem cell 1 (5), 555-567, 2007
|College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer|
ME Hammond, DF Hayes, M Dowsett, DC Allred, KL Hagerty, S Badve, ...
J Clin Oncol 28 (16), 2784-2795, 2010
|Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice …|
AC Wolff, MEH Hammond, DG Hicks, M Dowsett, LM McShane, ...
Archives of Pathology and Laboratory Medicine 138 (2), 241-256, 2014
|American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer|
AC Wolff, MEH Hammond, JN Schwartz, KL Hagerty, DC Allred, RJ Cote, ...
Archives of pathology & laboratory medicine 131 (1), 18-43, 2007
|American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in …|
MEH Hammond, DF Hayes, M Dowsett, DC Allred, KL Hagerty, S Badve, ...
Archives of pathology & laboratory medicine 134 (7), e48-e72, 2010
|American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer|
L Harris, H Fritsche, R Mennel, L Norton, P Ravdin, S Taube, ...
Journal of clinical oncology 25 (33), 5287-5312, 2007
|Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013|
A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ...
Annals of oncology 24 (9), 2206-2223, 2013
|EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells|
CG Kleer, Q Cao, S Varambally, R Shen, I Ota, SA Tomlins, D Ghosh, ...
Proceedings of the National Academy of Sciences 100 (20), 11606-11611, 2003
|Prognostic factors in breast cancer: College of American Pathologists consensus statement 1999|
PL Fitzgibbons, DL Page, D Weaver, AD Thor, DC Allred, GM Clark, ...
Archives of pathology & laboratory medicine 124 (7), 966-978, 2000
|ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer|
GY Locker, S Hamilton, J Harris, JM Jessup, N Kemeny, JS Macdonald, ...
Journal of clinical oncology 24 (33), 5313-5327, 2006
|Revision of the American Joint Committee on Cancer staging system for breast cancer|
SE Singletary, C Allred, P Ashley, LW Bassett, D Berry, KI Bland, ...
Journal of clinical oncology 20 (17), 3628-3636, 2002
|Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast …|
IC Henderson, DA Berry, GD Demetri, CT Cirrincione, LJ Goldstein, ...
Journal of clinical oncology 21 (6), 976-983, 2003
|A second generation of multivariate analysis. 2. Measurement and evaluation|
Praeger Publishers, 1982
|Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015|
AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ...
Annals of oncology 26 (8), 1533-1546, 2015
|Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group|
M Dowsett, TO Nielsen, R A’Hern, J Bartlett, RC Coombes, J Cuzick, ...
Journal of the National cancer Institute 103 (22), 1656-1664, 2011
|Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing …|
MD Pegram, A Lipton, DF Hayes, BL Weber, JM Baselga, D Tripathy, ...
Journal of clinical oncology 16 (8), 2659-2671, 1998
|American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict …|
CJ Allegra, JM Jessup, MR Somerfield, SR Hamilton, EH Hammond, ...
Journal of clinical oncology 27 (12), 2091-2096, 2009
|Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a …|
KS Albain, WE Barlow, S Shak, GN Hortobagyi, RB Livingston, IT Yeh, ...
The lancet oncology 11 (1), 55-65, 2010